Key result
NOACs significantly reduced the risk of VTE and VTE-related death compared with aspirin, with apixaban demonstrating the most favorable bleeding profile compared with other NOACs, warfarin, and aspirin.
Why the study?
Do NOACs reduce VTE and VTE-related death compared to aspirin, warfarin, or placebo in adults requiring extended treatment of VTE?
Network Meta-Analysis
Do NOACs reduce VTE and VTE-related death compared to aspirin, warfarin, or placebo in adults requiring extended treatment of VTE?
NOACs are effective for the extended prevention of VTE, with apixaban demonstrating the most favorable bleeding safety profile among oral anticoagulants.
Answers are grounded in this paper and cite their sources.
Supports NOAC preference over aspirin for extended VTE prevention; extends prior trials by ranking apixaban's superior bleeding safety.
BACKGROUND: Historically, warfarin or aspirin have been the recommended therapeutic options for the extended treatment (>3 months) of VTE. Data from Phase III randomised controlled trials (RCTs) are now available for non-VKA oral anticoagulants (NOACs) in this indication. The current systematic review and network meta-analysis (NMA) were conducted to compare the efficacy and safety of anticoagulants for the extended treatment of VTE. METHODS: Electronic databases (accessed July 2014 and updated April 2016) were systematically searched to identify RCTs evaluating apixaban, aspirin, dabigatran, edoxaban, rivaroxaban, and warfarin for the extended treatment of VTE. Eligible studies included adults with an objectively confirmed deep vein thrombosis, pulmonary embolism or both. A fixed-effect Bayesian NMA was conducted, and results were presented as relative risks (RRs). Sensitivity analyses examining (i) the dataset employed according to the time frame for outcome assessment (ii) the model used for the NMA were conducted. RESULTS: Eleven Phase III RCTs (examining apixaban, aspirin, dabigatran, rivaroxaban, warfarin and placebo) were included. The risk of the composite efficacy outcome (VTE and VTE-related death) was statistically significantly lower with the NOACs and warfarin INR 2.0-3.0 compared with aspirin, with no significant differences between the NOACs. Treatment with apixaban (RR 0.23, 95% CrI 0.10, 0.55) or dabigatran (RR 0.55, 95% Crl 0.43, 0.71) was associated with a statistically significantly reduced risk of 'major or clinically relevant non-major bleed' compared with warfarin INR 2.0-3.0. Apixaban also showed a significantly reduced risk compared with dabigatran (RR 0.42, 95% Crl 0.18, 0.97) and rivaroxaban (RR 0.23, 95% Crl 0.09, 0.59). Sensitivity analyses indicate that results were dependent on the dataset, but not on the type of NMA model employed. CONCLUSIONS: Results from the NMA indicate that NOACs are an effective treatment for prevention of VTE or VTE-related death) in the extended treatment setting. However, bleeding risk differs between potential treatments, with apixaban reporting the most favourable profile compared with other NOACs, warfarin INR 2.0-3.0, and aspirin.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2016) conducted a network meta-analysis in Venous Thromboembolism (VTE). Non-VKA oral anticoagulants (apixaban, dabigatran, rivaroxaban) vs. Aspirin, warfarin INR 2.0-3.0, or placebo was evaluated on Composite of VTE and VTE-related death (Apixaban vs. Aspirin comparison) (RR 0.28, 95% CI 0.14-0.51). NOACs significantly reduced the risk of VTE and VTE-related death compared with aspirin, with apixaban demonstrating the most favorable bleeding profile compared with other NOACs, warfarin, and aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: